Q2 2025 Eli Lilly and Co Earnings Call Transcript
Key Points
- Eli Lilly and Co (LLY) reported a 38% revenue growth compared to Q2 2024, driven by key products such as Mounjaro and Zepbound.
- The company achieved positive top-line data from the ATTAIN-1 orforglipron trial, showing significant weight loss and improvements in metabolic health markers.
- Eli Lilly and Co (LLY) raised its revenue and earnings per share guidance due to strong financial performance in the first half of 2025.
- The company announced and closed the acquisition of SiteOne Therapeutics and Verve Therapeutics, expanding its pain portfolio and genetic medicines for cardiovascular disease.
- Eli Lilly and Co (LLY) made progress in bringing new manufacturing capacity online, increasing production capabilities significantly compared to the previous year.
- The pricing environment remains challenging, with an 8% decline in price in the US market despite strong volume growth.
- There is concern over the impact of CVS pharmacy benefit manager excluding Zepbound from its template formulary insurance plans, which could affect prescription growth.
- The company faces ongoing challenges with drug pricing reform discussions and the potential impact of foreign price controls on the US market.
- Eli Lilly and Co (LLY) is experiencing increased marketing, selling, and administrative expenses, which rose by 30% to support new product launches.
- The company is dealing with the issue of compounded drugs in the market, which poses a risk to patient safety and affects the business.
Thank you for holding. We look forward to talking with you soon. Please hold the line and we'll be right back with you.
Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q2 2025 earnings conference call. (Operator Instructions) I would now like to turn the conference over to your host, Mike Czapar, Senior Vice President of Investor Relations. Please go ahead.
Good morning. Thank you for joining us for Eli Lilly Company's Q2 2025 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Lucas Montarce, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer and President of Lilly Immunology; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly USA and Global Customer Capabilities; Jacob Van Naarden, President of Lilly Oncology; Patrik Jonsson, President of Lilly International; and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
